Parathyroid hormone (PTH) and its analogue, teriparatide, are a new class of osteoporosis treatments
called bone formation agents. Teriparatide injection (Forteo) is the first medication approved by Health
Canada in this new class.
How does teriparatide injection work?
The mechanism by which bone is constantly renewed is called bone remodelling. Teriparatide injection works
in a novel way on the bone remodelling process so that new bone is generated and added to the skeleton faster
than old bone is broken down. It does this by activating the osteoblast (bone-building) cells.
How effective is it?
Teriparatide injection has been shown to increase bone density and reduce the risk of both vertebral
fractures and other fractures associated with osteoporosis.
Who can take it?
It is used for the treatment of postmenopausal women with severe osteoporosis who are at high risk of
fracture or who have failed or are intolerant to previous osteoporosis therapy. It is also used to increase
bone mass in men with primary or hypogonadal (low testosterone) severe osteoporosis who have failed or are
intolerant to previous osteoporosis therapy. It is also indicated for the treatment of osteoporosis
associated with sustained systemic glucocorticoid therapy in men and women who are at increased risk of
fracture.
How is it taken?
It is taken as a sub-cutaneous injection into the thigh or abdominal wall, 20 mcg (micrograms) once a day.
This medication should not be taken for longer than 24 months.
Are there side effects?
Possible side effects include dizziness, nausea and leg cramps.
